Abcellera Biologics is trading at $6.13 (5.1% up) ahead of its Q2 2026 earnings release on August 5, with investor attention centered on upcoming clinical milestones.
- Analysts are focused on the progress and upcoming readout for ABCL635, which is considered the key near-term catalyst for the company.
- While current revenue is expected to remain low, the stock is benefiting from a strong biotech tape and a broader market rally.